151 related articles for article (PubMed ID: 32557236)
1. Epi proColon
Shirley M
Mol Diagn Ther; 2020 Aug; 24(4):497-503. PubMed ID: 32557236
[TBL] [Abstract][Full Text] [Related]
2. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study.
Johnson DA; Barclay RL; Mergener K; Weiss G; König T; Beck J; Potter NT
PLoS One; 2014; 9(6):e98238. PubMed ID: 24901436
[TBL] [Abstract][Full Text] [Related]
3. Epi proColon
Lamb YN; Dhillon S
Mol Diagn Ther; 2017 Apr; 21(2):225-232. PubMed ID: 28155091
[TBL] [Abstract][Full Text] [Related]
4. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening.
Wu D; Zhou G; Jin P; Zhu J; Li S; Wu Q; Wang G; Sheng J; Wang J; Song L; Han X; Qian J
J Mol Diagn; 2016 Jul; 18(4):535-45. PubMed ID: 27133379
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
6. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
[TBL] [Abstract][Full Text] [Related]
7. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
8. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
Jin P; Kang Q; Wang X; Yang L; Yu Y; Li N; He YQ; Han X; Hang J; Zhang J; Song L; Han Y; Sheng JQ
J Gastroenterol Hepatol; 2015 May; 30(5):830-3. PubMed ID: 25471329
[TBL] [Abstract][Full Text] [Related]
9. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location.
Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298
[TBL] [Abstract][Full Text] [Related]
10. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma.
Potter NT; Hurban P; White MN; Whitlock KD; Lofton-Day CE; Tetzner R; Koenig T; Quigley NB; Weiss G
Clin Chem; 2014 Sep; 60(9):1183-91. PubMed ID: 24938752
[TBL] [Abstract][Full Text] [Related]
11. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.
Tóth K; Sipos F; Kalmár A; Patai AV; Wichmann B; Stoehr R; Golcher H; Schellerer V; Tulassay Z; Molnár B
PLoS One; 2012; 7(9):e46000. PubMed ID: 23049919
[TBL] [Abstract][Full Text] [Related]
12. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
[TBL] [Abstract][Full Text] [Related]
13. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening.
Zhao G; Li H; Yang Z; Wang Z; Xu M; Xiong S; Li S; Wu X; Liu X; Wang Z; Zhu Y; Ma Y; Fei S; Zheng M
Cancer Med; 2019 Sep; 8(12):5619-5628. PubMed ID: 31407497
[TBL] [Abstract][Full Text] [Related]
14. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis.
Song L; Jia J; Peng X; Xiao W; Li Y
Sci Rep; 2017 Jun; 7(1):3032. PubMed ID: 28596563
[TBL] [Abstract][Full Text] [Related]
15. The SEPT9 gene methylation assay is capable of detecting colorectal adenoma in opportunistic screening.
Song L; Peng X; Li Y; Xiao W; Jia J; Dong C; Gong Y; Zhou G; Han X
Epigenomics; 2017 May; 9(5):599-610. PubMed ID: 28470092
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
Ladabaum U; Allen J; Wandell M; Ramsey S
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Church TR; Wandell M; Lofton-Day C; Mongin SJ; Burger M; Payne SR; Castaños-Vélez E; Blumenstein BA; Rösch T; Osborn N; Snover D; Day RW; Ransohoff DF;
Gut; 2014 Feb; 63(2):317-25. PubMed ID: 23408352
[TBL] [Abstract][Full Text] [Related]
18.
Laven-Law G; Kichenadasse G; Young GP; Symonds EL; Winter JM
Biomarkers; 2024 Jun; 29(4):194-204. PubMed ID: 38644767
[TBL] [Abstract][Full Text] [Related]
19. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany.
Adler A; Geiger S; Keil A; Bias H; Schatz P; deVos T; Dhein J; Zimmermann M; Tauber R; Wiedenmann B
BMC Gastroenterol; 2014 Oct; 14():183. PubMed ID: 25326034
[TBL] [Abstract][Full Text] [Related]
20. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
